Article citationsMore>>

Kurokawa, K., Hara, M., Iwakami, S.I., Genda, T., Iwakami, N., Miyashita, Y., Fujioka, M., Sasaki, S. and Takahashi, K. (2019) Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma. Internal Medicine, 58, 3283-3287.
https://doi.org/10.2169/internalmedicine.2591-18

has been cited by the following article:

• TITLE: Anti-Tuberculosis Drug Induced Liver Injury and Ursodeoxycholic Acid

  AUTHORS: Susanne M. Lang, Emad Al-Nemnem, Helmut Schiffl

  KEYWORDS: Ursodeoxycholic Acid, Hepatotoxicity, Rifampicin, Isoniazid, Pyrazinamide, Tuberculosis

  JOURNAL NAME: Journal of Tuberculosis Research, Vol.8 No.2, June 29, 2020

  ABSTRACT: Hepatotoxicity induced by standard anti-tuberculosis drugs (isoniazid, rifampicin, pyrazinamide) can result in significant morbidity and, rarely, even mortality. This major adverse side-effect of anti-tuberculosis treatment has a negative impact on patient adherence and patient outcomes as well as on tuberculosis control. Early recognition and prompt withdrawal of the offending drugs are the most critical interventions in the management of anti-tuberculosis drug-induced liver injury. No drug or herbal extract has been shown until recently to prevent or reverse anti-tuberculosis drug-induced hepatotoxicity. Ursodeoxycholic acid is the only FDA approved drug for the treatment of primary biliary cholangitis and has also been successfully used in various cholestatic liver diseases. Although still experimental, recent controlled clinical studies suggested that oral administration of ursodeoxycholic acid may prevent the onset of anti-tuberculosis drug-induced liver injury and accelerate the recovery of liver injury. These clinical data are supported by experimental models of anti-tuberculosis drug-induced hepatotoxicity. There is an urgent need for further randomized clinical trials to document the promising hepatoprotective properties of ursodeoxycholic acid.